TY - JOUR
T1 - Uric acid in chronic heart failure
T2 - A measure of the anaerobic threshold
AU - Leyva, Francisco
AU - Chua, Tuan Peng
AU - Anker, Stefan D.
AU - Coats, Andrew J S
PY - 1998
Y1 - 1998
N2 - The anaerobic threshold (AT) is a measure of the balance between aerobic and anaerobic cellular metabolism. Hyperuricemia occurs in conditions that involve an imbalance between cellular oxygen consumption and carbon dioxide production, such as chronic heart failure (CHF). We therefore hypothesized that in CHF, serum uric acid might be related to the AT. Patients with CHF (n = 40, aged 58.7 ± 1.9 years; New York Heart Association Class I-IV; maximal oxygen consumption [MV̇(O2)], 18.7 ± 01.1 mL/kg/min; left ventricular ejection fraction, 26% ± 2%) and 10 age-matched healthy controls underwent measurement of the serum uric acid level at rest and assessment of the AT. This was derived from MV̇(O2) and the regression slope relating minute ventilation to carbon dioxide output (VE - V̇(CO2)) during a maximal treadmill exercise test. Compared with the healthy controls, patients with CHF had a lower AT (11.8 ± 0.7 v 16.9 ± 1.1 mL/kg/min, P<.001) and a higher serum uric acid concentration (493.8 ± 22.4 v 308.7 ± 21.5 μmol/L, P <.001). In univariate analyses of the CHF group, the AT correlated with serum uric acid (r = -.56, P <.001; AT = 19.93- (0.016 · uric acid), R2 = .31, P <.001) and plasma creatinine (r = -.43, P <.01), but not with the diuretic dose. In stepwise regression analyses of the CHF group, serum uric acid emerged as a predictor of the AT (standardized coefficient = -.56, P <.001), whereas the diuretic dose and plasma creatinine failed to enter into the final models (multiple R2 = .31, P <.001). In conclusion, in CHF there is an inverse relationship between the AT and the resting serum uric acid concentration. This is consistent with the known links between uric acid production and the imbalance in aerobic/anaerobic metabolism that occur in CHF. These findings provide the basis for using the simple measurement of the serum uric acid level as a surrogate measure of the AT.
AB - The anaerobic threshold (AT) is a measure of the balance between aerobic and anaerobic cellular metabolism. Hyperuricemia occurs in conditions that involve an imbalance between cellular oxygen consumption and carbon dioxide production, such as chronic heart failure (CHF). We therefore hypothesized that in CHF, serum uric acid might be related to the AT. Patients with CHF (n = 40, aged 58.7 ± 1.9 years; New York Heart Association Class I-IV; maximal oxygen consumption [MV̇(O2)], 18.7 ± 01.1 mL/kg/min; left ventricular ejection fraction, 26% ± 2%) and 10 age-matched healthy controls underwent measurement of the serum uric acid level at rest and assessment of the AT. This was derived from MV̇(O2) and the regression slope relating minute ventilation to carbon dioxide output (VE - V̇(CO2)) during a maximal treadmill exercise test. Compared with the healthy controls, patients with CHF had a lower AT (11.8 ± 0.7 v 16.9 ± 1.1 mL/kg/min, P<.001) and a higher serum uric acid concentration (493.8 ± 22.4 v 308.7 ± 21.5 μmol/L, P <.001). In univariate analyses of the CHF group, the AT correlated with serum uric acid (r = -.56, P <.001; AT = 19.93- (0.016 · uric acid), R2 = .31, P <.001) and plasma creatinine (r = -.43, P <.01), but not with the diuretic dose. In stepwise regression analyses of the CHF group, serum uric acid emerged as a predictor of the AT (standardized coefficient = -.56, P <.001), whereas the diuretic dose and plasma creatinine failed to enter into the final models (multiple R2 = .31, P <.001). In conclusion, in CHF there is an inverse relationship between the AT and the resting serum uric acid concentration. This is consistent with the known links between uric acid production and the imbalance in aerobic/anaerobic metabolism that occur in CHF. These findings provide the basis for using the simple measurement of the serum uric acid level as a surrogate measure of the AT.
UR - http://www.scopus.com/inward/record.url?scp=0031723208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031723208&partnerID=8YFLogxK
U2 - 10.1016/S0026-0495(98)90293-1
DO - 10.1016/S0026-0495(98)90293-1
M3 - Article
C2 - 9751248
AN - SCOPUS:0031723208
VL - 47
SP - 1156
EP - 1159
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 9
ER -